S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:NTEC

Intec Pharma - NTEC Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$9.15
▼
$36.20
52-Week Range
N/A
Volume
988,300 shs
Average Volume
543,436 shs
Market Capitalization
$8.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NTEC stock logo

About Intec Pharma (NASDAQ:NTEC) Stock

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Receive NTEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

NTEC Stock News Headlines

March 18, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)
March 2, 2023 | marketwatch.com
Fibromyalgia Treatment Market Forecast: An Analysis of Industry Trends for 2023-2028
March 24, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
February 19, 2023 | marketwatch.com
Global Parkinson’s Disease Treatment Market Opportunities, Business Statistics Research Report 2030 By VMReports
February 15, 2023 | marketwatch.com
Fibromyalgia Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of Solutions
January 30, 2023 | marketwatch.com
Syphilis Rapid Test Kit Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028
January 23, 2023 | marketwatch.com
Fibromyalgia Treatment Market Industry Updates, New Opportunities, Major Strategies, And Forecast 2028
December 29, 2022 | marketwatch.com
With 1.7% CAGR, Fibromyalgia Treatment Market 2023 Is Flourishing Around the World by 2028 | 116 Pages Report
March 24, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
December 21, 2022 | marketwatch.com
Fibromyalgia Treatment Market (New Report) to Witness A Pronounce Growth During 2023-2028 | 116 Pages Report
October 17, 2022 | marketwatch.com
Fibromyalgia Treatment Market Size in 2022 with Latest Report of 100 Pages & Business Forecast up to 2028 by Value Chain Analysis | No of Pages 100
August 28, 2022 | marketwatch.com
Fibromyalgia Treatment Market Size and Share 2022 Analysis Report by Industry Trends, Drivers, Applications, Sale and Forecast to 2028
July 5, 2022 | investing.com
World Holdings Co Ltd (2429)
June 4, 2022 | finanznachrichten.de
Beroe Inc.: Beroe partners with Mintec to power its intelligence offering with market-leading commodity price data
December 18, 2021 | finanznachrichten.de
EXEL INDUSTRIES :2020-2021 Full-year results: Significant improvement in margins combined with a sharp reduction in debt
December 1, 2021 | markets.businessinsider.com
Genetron earnings preview: what Wall Street is expecting
November 12, 2021 | markets.businessinsider.com
Here's what Wall Street expects from Cipher Pharmaceuticals's earnings
August 3, 2021 | finance.yahoo.com
Intec Closes Merger with Decoy Biosystems
August 3, 2021 | finance.yahoo.com
Intec Announces Expected Closing Date of Decoy Merger
July 29, 2021 | marketwatch.com
Intec Parent Shares Up 60%
July 26, 2021 | msn.com
BRIEF-Intec Announces $30 Mln Private Placement Ahead Of Decoy Merger
July 26, 2021 | marketwatch.com
Intec Pharma in $30 Million Private Placement
July 26, 2021 | finance.yahoo.com
Intec Announces $30 Million Private Placement Ahead of Decoy Merger
July 25, 2021 | nasdaq.com
Intec Pharma Ltd. Ordinary Shares (NTEC)
March 27, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intec Pharma Ltd. - NTEC
March 23, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intec Pharma Ltd.
March 22, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Intec Pharma Ltd. Merger
See More Headlines
Receive NTEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

NTEC Company Calendar

Last Earnings
5/17/2021
Today
3/24/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTEC
CUSIP
N/A
CIK
1638381
Web
www.intecpharma.com
Phone
(722) 586-4657
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($16.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,130,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-96.37%
Return on Assets
-68.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.34
Quick Ratio
2.34

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.18 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
898,000
Free Float
N/A
Market Cap
$8.65 million
Optionable
Optionable
Beta
0.83

Key Executives

  • Jeffrey A. Meckler
    Vice Chairman & Chief Executive Officer
  • Nir Sassi
    President & Chief Financial Officer
  • Michael James Newman
    Director & Chief Scientific Officer
  • Anna Hotovely-Salomon
    Director-Clinical Affairs
  • Walt A. Linscott
    Chief Business Officer

Key Competitors

View All Competitors













NTEC Stock - Frequently Asked Questions

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.48) by $0.36.

When did Intec Pharma's stock split?

Intec Pharma's stock reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO) and Acasti Pharma (ACST).

When did Intec Pharma IPO?

(NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How much money does Intec Pharma make?

Intec Pharma (NASDAQ:NTEC) has a market capitalization of $0.00. The biotechnology company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The official website for the company is www.intecpharma.com. The biotechnology company can be reached via phone at (722) 586-4657 or via email at ir@intec-us.com.

This page (NASDAQ:NTEC) was last updated on 3/24/2023 by MarketBeat.com Staff